Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Flinders Health and Medical Research Institute (FHMRI) College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Hum Genomics. 2024 Jun 11;18(1):61. doi: 10.1186/s40246-024-00620-w.
Trace Amine Associated Receptor 1 (TAAR1) is a novel pharmaceutical target under investigation for the treatment of several neuropsychiatric conditions. TAAR1 single nucleotide variants (SNV) have been found in patients with schizophrenia and metabolic disorders. However, the frequency of variants in geographically diverse populations and the functional effects of such variants are unknown. In this study, we aimed to characterise the distribution of TAAR1 SNVs in five different WHO regions using the Database of Genotypes and Phenotypes (dbGaP) and conducted a critical computational analysis using available TAAR1 structural data to identify SNVs affecting ligand binding and/or functional regions. Our analysis shows 19 orthosteric, 9 signalling and 16 micro-switch SNVs hypothesised to critically influence the agonist induced TAAR1 activation. These SNVs may non-proportionally influence populations from discrete regions and differentially influence the activity of TAAR1-targeting therapeutics in genetically and geographically diverse populations. Notably, our dataset presented with orthosteric SNVs D103N (found only in the South-East Asian Region and Western Pacific Region) and T194A (found only in South-East Asian Region), and 2 signalling SNVs (V125A/T252A, found in African Region and commonly, respectively), all of which have previously demonstrated to influence ligand induced functions of TAAR1. Furthermore, bioinformatics analysis using SIFT4G, MutationTaster 2, PROVEAN and MutationAssessor predicted all 16 micro-switch SNVs are damaging and may further influence the agonist activation of TAAR1, thereby possibly impacting upon clinical outcomes. Understanding the genetic basis of TAAR1 function and the impact of common mutations within clinical populations is important for the safe and effective utilisation of novel and existing pharmacotherapies.
追踪胺相关受体 1(TAAR1)是一种新的药物靶点,正在研究用于治疗几种神经精神疾病。已经在精神分裂症和代谢紊乱患者中发现了 TAAR1 单核苷酸变异(SNV)。然而,在地理上不同的人群中变异的频率以及这些变异的功能影响尚不清楚。在这项研究中,我们旨在使用基因型和表型数据库(dbGaP)对五个不同的世界卫生组织区域中的 TAAR1 SNV 分布进行特征描述,并使用可用的 TAAR1 结构数据进行关键的计算分析,以确定影响配体结合和/或功能区域的 SNV。我们的分析显示,有 19 个正位、9 个信号和 16 个微开关 SNV 被假设会严重影响激动剂诱导的 TAAR1 激活。这些 SNV 可能不成比例地影响来自不同区域的人群,并在遗传和地理上不同的人群中对靶向 TAAR1 的治疗药物的活性产生不同的影响。值得注意的是,我们的数据集呈现了正位 SNV D103N(仅在东南亚地区和西太平洋地区发现)和 T194A(仅在东南亚地区发现)以及 2 个信号 SNV(V125A/T252A,在非洲地区发现,分别为常见),所有这些 SNV 先前都证明影响 TAAR1 配体诱导的功能。此外,使用 SIFT4G、MutationTaster 2、PROVEAN 和 MutationAssessor 进行的生物信息学分析预测所有 16 个微开关 SNV 都是有害的,可能进一步影响 TAAR1 的激动剂激活,从而可能影响临床结果。了解 TAAR1 功能的遗传基础以及临床人群中常见突变的影响对于新型和现有药物治疗的安全有效利用非常重要。